Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS -2.57%19 EBIT per Share is ₹57.75 as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 813 Drug Manufacturers companies, Curis Lifesciences ranks better than 99.63% on this metric.
Curis Lifesciences's EBIT per Share for the
six
months ended in Mar. 2026 was ₹57.75.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹57.75.
During the past 12 months, the average EBIT per Share Growth Rate of Curis Lifesciences was 388.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 161.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Curis Lifesciences's EBIT per Share or its related term are showing as below:
NSE:CURIS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 161.1 Med: 161.1 Max: 161.1
Current: 161.1
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Curis Lifesciences was 161.10% per year. The lowest was 161.10% per year. And the median was 161.10% per year.
NSE:CURIS's 3-Year EBIT Growth Rate is ranked better than 99.63% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:CURIS: 161.10
Curis Lifesciences (NSE:CURIS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Curis Lifesciences EBIT per Share Related Terms
Curis Lifesciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹57.75
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a EBIT per Share of ₹57.75 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curis Lifesciences and its competitors. According to the industry distribution chart, Curis Lifesciences ranks #3 out of 813 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Curis Lifesciences' EBIT per Share too high?
Curis Lifesciences' current EBIT per Share is ₹57.75. Based on the distribution chart, Curis Lifesciences ranks #3 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #3 out of 813 companies for EBIT per Share. This places Curis Lifesciences in the top 0% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current EBIT per Share is ₹57.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current EBIT per Share of ₹57.75. The current EBIT per Share is ₹57.75. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current EBIT per Share is ₹57.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
